Semi-Annual Report — FY2026 H1
What Chiome Bioscience Inc. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-13View the original on EDINET
How much it says
60Detailed
What moved here
23named for the first time
Its own wording
17terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, revenue was ¥273.659 million, and operating loss, ordinary loss and interim net loss all narrowed year on year. In terms of business operations, the filing describes progress in Phase 1 clinical trials of the company's antibodies, including CBA-1205 and CBA-1535, and the launch of new projects under the business partnership with Axcelead in the IDD business.
Komori's summary of this document, not the document's own words.60Detailed
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
54
Typical
49
Typical
75
Very detailed
53
Typical
71
Detailed
62
Detailed
60
Detailed
55
Typical
50
Typical
R&D spend4億円Money spent making new things.
Cash left over-5億円Cash from the business, less what went into equipment.
Spent on equipment4百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.